Haglund C, Kuusela P, Jalanko H, Roberts P J
Int J Cancer. 1987 Apr 15;39(4):477-81. doi: 10.1002/ijc.2910390412.
CA 50 is a new tumor marker based on a monoclonal antibody (MAb) against a human colorectal carcinoma cell line. The CA 50 antigen is similar, but not identical, to the tumor marker CA 19-9. The serum concentrations of CA 50 were measured by an immunoradiometric assay (CA 50 IRMA) in 95 patients with pancreatic cancer and in 94 patients with benign pancreatic, biliary and hepatocellular diseases. The CA 50 concentration was above the cut-off limit of 17 U/ml in 71% of the patients with pancreatic cancer. Elevated CA 50 levels were also seen in 29% of the patients with benign diseases (up to 250 U/ml), especially in patients with extra-hepatic cholestasis (34%) and hepatocellular jaundice (46%). The results of the immunoradiometric assay were compared to those of the commercially available CA 50 RIA inhibition test. The sensitivities of the two CA 50 assays for pancreatic cancer were similar, but the specificity of the IRMA assay was higher. The CA 50 and CA 19-9 values showed a strong positive correlation and the assay parameters of the tests were almost similar. CA 50 seems a promising tumor marker in the detection and follow-up of patients with pancreatic cancer.
CA 50是一种基于针对人结肠癌细胞系的单克隆抗体（MAb）的新型肿瘤标志物。CA 50抗原与肿瘤标志物CA 19-9相似，但并不完全相同。采用免疫放射分析（CA 50 IRMA）检测了95例胰腺癌患者以及94例患有胰腺、胆管和肝细胞良性疾病患者的血清CA 50浓度。71%的胰腺癌患者CA 50浓度高于17 U/ml的临界值。29%的良性疾病患者（最高达250 U/ml）也出现CA 50水平升高，尤其是肝外胆汁淤积患者（34%）和肝细胞性黄疸患者（46%）。将免疫放射分析结果与市售CA 50 RIA抑制试验结果进行了比较。两种CA 50检测方法对胰腺癌的敏感性相似，但IRMA检测方法的特异性更高。CA 50和CA 19-9值呈强正相关，且检测的分析参数几乎相似。CA 50似乎是胰腺癌患者检测和随访中有前景的肿瘤标志物。
